DGX Form 4: Officer acquires 15 shares at $189.077
Quest Diagnostics (DGX) reported an insider transaction on Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics (DGX) reported an insider transaction on Form 4. SVP & Chief Commercial Officer Mark E. Delaney acquired 15 shares of common stock on 10/21/2025 at $189.077 per share via a dividend reinvestment plan. Following the transaction, he beneficially owns 7,530 shares, held directly. The filing notes the transaction is eligible for deferred reporting under Rule 16a-6 and was reported early.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 15 | $189.077 | $3K |
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did DGX disclose in this Form 4 filing?
Who is the reporting person in DGX's Form 4?
What was the method of acquisition in the DGX transaction?
Was this DGX transaction reported early?
AI-generated analysis. How Rhea-AI works. Not financial advice.